v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Equity
Additional Paid in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   54,440,013      
Beginning balance at Dec. 31, 2024 $ 491,875 $ 7 $ 712,884   $ (221,016)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   88,962      
Issuance of common stock upon exercise of stock options 477   477    
Stock-based compensation 3,451   3,451    
Net loss (36,846)       (36,846)
Ending balance (in shares) at Mar. 31, 2025   54,528,975      
Ending balance at Mar. 31, 2025 458,957 $ 7 716,812   (257,862)
Beginning balance (in shares) at Dec. 31, 2024   54,440,013      
Beginning balance at Dec. 31, 2024 491,875 $ 7 712,884   (221,016)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (64,234)        
Ending balance (in shares) at Jun. 30, 2025   54,556,078      
Ending balance at Jun. 30, 2025 435,196 $ 7 720,439   (285,250)
Beginning balance (in shares) at Mar. 31, 2025   54,528,975      
Beginning balance at Mar. 31, 2025 458,957 $ 7 716,812   (257,862)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   27,103      
Issuance of common stock upon exercise of stock options 135   135    
Stock-based compensation 3,492   3,492    
Net loss (27,388)       (27,388)
Ending balance (in shares) at Jun. 30, 2025   54,556,078      
Ending balance at Jun. 30, 2025 $ 435,196 $ 7 720,439   (285,250)
Beginning balance (in shares) at Dec. 31, 2025 56,600,724 56,600,724      
Beginning balance at Dec. 31, 2025 $ 401,452 $ 7 760,168 $ 243 (358,966)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, and accompanying pre-funded warrants, net of offering cost (in shares)   8,581,250      
Issuance of common stock, and accompanying pre-funded warrants, net of issuance cost 161,763 $ 1 161,762    
Issuance of common stock upon exercise of stock options (in shares)   365,063      
Issuance of common stock upon exercise of stock options 1,582   1,582    
Stock-based compensation 5,858   5,858    
Unrealized loss on marketable securities, net of tax (486)     (486)  
Net loss (56,211)       (56,211)
Ending balance (in shares) at Mar. 31, 2026   65,547,037      
Ending balance at Mar. 31, 2026 $ 513,958 $ 8 929,370 (243) (415,177)
Beginning balance (in shares) at Dec. 31, 2025 56,600,724 56,600,724      
Beginning balance at Dec. 31, 2025 $ 401,452 $ 7 760,168 243 (358,966)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) 749,154        
Net loss $ (111,647)        
Ending balance (in shares) at Jun. 30, 2026 65,931,128 65,931,128      
Ending balance at Jun. 30, 2026 $ 468,768 $ 8 939,940 (567) (470,613)
Beginning balance (in shares) at Mar. 31, 2026   65,547,037      
Beginning balance at Mar. 31, 2026 513,958 $ 8 929,370 (243) (415,177)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   384,091      
Issuance of common stock upon exercise of stock options 2,332   2,332    
Stock-based compensation 8,238   8,238    
Unrealized loss on marketable securities, net of tax (324)     (324)  
Net loss $ (55,436)       (55,436)
Ending balance (in shares) at Jun. 30, 2026 65,931,128 65,931,128      
Ending balance at Jun. 30, 2026 $ 468,768 $ 8 $ 939,940 $ (567) $ (470,613)